UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 59

Sortiert nach

Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines

European journal of cancer (1990), 2019-09, Vol.118, p.10-34

2019

Volltextzugriff (PDF)

Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016

European journal of cancer (1990), 2016-08, Vol.63, p.201-217

2016

Volltextzugriff (PDF)

Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline

European journal of cancer (1990), 2015-09, Vol.51 (14), p.1989-2007

2015

Volltextzugriff (PDF)

Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline

European journal of cancer (1990), 2015-11, Vol.51 (17), p.2604-2608

2015

Volltextzugriff (PDF)

Development of an Image Analysis-Based Prognosis Score Using Google's Teachable Machine in Melanoma

Cancers, 2022-04, Vol.14 (9), p.2243

2022

Volltextzugriff (PDF)

Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas

Cancers, 2021-07, Vol.13 (15), p.3864

2021

Volltextzugriff (PDF)

Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

Journal for immunotherapy of cancer, 2019-12, Vol.7 (1), p.343-343, Article 343

2019

Volltextzugriff (PDF)

Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors

Cancer Immunology, Immunotherapy, 2021-04, Vol.70 (4), p.1089-1099

2021

Volltextzugriff (PDF)

The natural course of cutaneous melanoma

Journal of surgical oncology, 2004-07, Vol.86 (4), p.172-178

2004

Volltextzugriff (PDF)

Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry

Cancers, 2021-12, Vol.13 (23), p.6141

2021

Volltextzugriff (PDF)

Prognostic Factors of Thin Cutaneous Melanoma: An Analysis of the Central Malignant Melanoma Registry of the German Dermatological Society

Journal of clinical oncology, 2004-09, Vol.22 (18), p.3660-3667

2004

Volltextzugriff (PDF)

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy

Journal for immunotherapy of cancer, 2021-12, Vol.9 (12), p.e003439

2021

Volltextzugriff (PDF)

Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic Cooperative Oncology Group

Journal of clinical oncology, 2005-12, Vol.23 (35), p.9001-9007

2005

Volltextzugriff (PDF)

S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies

British journal of cancer, 2018-08, Vol.119 (3), p.339-346

2018

Volltextzugriff (PDF)

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

The lancet oncology, 2016-09, Vol.17 (9), p.1248-1260

2016

Volltextzugriff (PDF)

Impact of Ulceration in Stages I to III Cutaneous Melanoma As Staged by the American Joint Committee on Cancer Staging System: An Analysis of the German Central Malignant Melanoma Registry

Journal of clinical oncology, 2004-11, Vol.22 (21), p.4376-4383

2004

Volltextzugriff (PDF)

Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

CA: a cancer journal for clinicians, 2017-11, Vol.67 (6), p.472-492

2017

Volltextzugriff (PDF)

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Clinical cancer research, 2016-11, Vol.22 (22), p.5487-5496

2016

Volltextzugriff (PDF)

Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells

Clinical cancer research, 2014-03, Vol.20 (6), p.1601-1609

2014

Volltextzugriff (PDF)

Identification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage I–IIA cutaneous melanoma

European journal of cancer (1990), 2023-03, Vol.182, p.77-86

2023

Volltextzugriff (PDF)

Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden

European journal of cancer (1990), 2019-12, Vol.123, p.83-91

2019

Volltextzugriff (PDF)

Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy

Cancer Immunology, Immunotherapy, 2018-12, Vol.67 (12), p.1845-1851

2018

Volltextzugriff (PDF)

Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2012

European journal of cancer (1990), 2012-10, Vol.48 (15), p.2375-2390

2012

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Aktive Filter

KollektioneBooks on EBSCOhost

ThemaOncology

ThemaPrognosis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(59)

Sprache

Englisch
(59)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

13 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines

Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016

Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial

Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline

Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline

Development of an Image Analysis-Based Prognosis Score Using Google's Teachable Machine in Melanoma

Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas

Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors

The natural course of cutaneous melanoma

Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry

Prognostic Factors of Thin Cutaneous Melanoma: An Analysis of the Central Malignant Melanoma Registry of the German Dermatological Society

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy

Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic Cooperative Oncology Group

S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Impact of Ulceration in Stages I to III Cutaneous Melanoma As Staged by the American Joint Committee on Cancer Staging System: An Analysis of the German Central Malignant Melanoma Registry

Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells

Identification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage I–IIA cutaneous melanoma

Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden

Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy

Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2012

Aktive Filter

Suchergebnisse filtern